Document is current
Any future updates will be listed below
-
Authors
Van Keer, Severien https://orcid.org/0000-0003-1842-7478
van den Helder, Rianne
Téblick, Laura https://orcid.org/0000-0002-7484-0956
De Smet, Annemie
Donders, Gilbert
Weyers, Steven
Doyen, Jean
van Trommel, Nienke
Mom, Constantijne H.
Verhoeve, Harold
Meijer, Chris J. L. M.
Bleeker, Maaike
Cornelis, Ann
Van de Vijver, Koen https://orcid.org/0000-0002-2026-9790
Delbecque, Katty
Lissenberg-Witte, Birgit
Vorsters, Alex https://orcid.org/0000-0002-0265-058X
Steenbergen, Renske D. M. https://orcid.org/0000-0002-2327-9839
- License Information
-
More Information
Article History
Received: 10 June 2025
Accepted: 25 February 2026
First Online: 12 March 2026
Competing interests
: Alex Vorsters is co-founder and former board member of Novosanis, a spin-off company of the University of Antwerp, and was minority shareholder until January 2019. Alex Vorsters holds patents related to this work. The University of Antwerp obtained unrestricted educational grants from Becton Dickinson, Hologic, and Roche. Renske DM Steenbergen and Chris JLM Meijer are co-founders and minority shareholders of Self-Screen B.V. Self-screen B.V. holds patents related to this work, and develops, manufactures, and licenses high-risk HPV and methylation marker assays. Renske DM Steenbergen declares consultancy fees from AstraZeneca. Chris JLM Meijer is part-time CEO of Self-screen BV and declares consultancy fees from Qiagen and Asieris pharma/Ismar Health care BV. All other authors declare no competing interests.
